Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announced a capital increase of 300k€ through the offsetting of debt owed to Cambria KOP BV, a Dutch investment company, and the emission of 196,080 shares of the Company. This operation strengthens the Company's net financial position and broadens its shareholder base, reflecting confidence in Ikonisys' future growth. Furthermore, it underscores the appreciation for the significant progress achieved over the past year in consolidating the new ALIKO Scientific group and advancing its mission in innovative cancer diagnostics.

The implementation of this capital increase, carried out with cancellation of shareholders' subscription rights through a private placement, was approved by the Board of Directors of the Issuer at its meeting held on December 30, 2024 (the "Capital Increase"). The new shares will be issued on the basis of the 17th resolution of the Issuer's shareholders' meeting held on September 30, 2024. The delivery of the new shares will take place on January 13, 2025. The Capital Increase did not require the approval of a notice ("prospectus") by the Autorité des marchés financiers (the "AMF").

The Issuer has issued a total of 196,080 new ordinary shares, with a par value of €0.5 each, to the investor, pursuant to article L. 225-129, 225-129-2 and 225-138 of the French Commercial Code, in accordance with the 17th resolution passed by its Annual General Meeting on September 30, 2024. The issuance price of the new shares issued under the Capital Increase, equal to €1.53 per share, represents a premium of approximately 3% on the Ikonisys share price at the close of January 8, 2025.

This capital increase does not inject new liquidity into the company, but offsets a debt towards Cambria KOP BV. As of December 31, 2023, and as mentioned in the annual financial report published on July 8, 2024, the Issuer's consolidated cash position amounted to €9.4k. In order to strengthen its financial resources, Ikonisys completed a capital increase of €1m on January 2, 2024 and more recently four capital increases for a total cumulative sum of €1.2m on June, July, August, October and November 2024. Taking into account the previously secured financing facility, the Company considers that it is now in a position to meet its financing needs for more than 12 months.

On the basis of the 13,261,485 shares outstanding, the impact on the shareholding of a shareholder holding 1% of the Issuer's capital prior to the transaction is as follows:

On a non-diluted basis On a diluted basis1
Before completion of the Capital Increase 1.00% 0.97 %
After issuance of the 196,080 shares resulting from the Capital Increase 0.99 % 0.96 %

1 Dilution takes into account the exercise of all outstanding dilutive instruments likely to result in the issuance of a maximum indicative number of 397,043 new shares.

Capital breakdown before and after completion of the Capital Increase

Before the Capital Increase:
Shareholder Number of shares % of share capital %of voting rights
Cambria Co-Investment Fund 5,268,989 39.73% 49.46%
Cambria Equity Partners 1,796,919 13.55% 16.66%
MC Consulting* 351,464 2.65% 3.67%
Redfish 4 listing Srl 233,333 1.76% 1.22%
CC Holding Srl 166,666 1.26% 0.87%
ETH Scientific Srl 2,000,000 15.08% 10.43%
Free float 3,444,114 25.97% 17.71%
Total 13,261,485 100% 100%
Self-owned shares 49,758

After the Capital Increase:
Shareholder Number of shares % of share capital %of voting rights
Cambria Co-Investment Fund 5,268,989 39.73% 49.46%
Cambria Equity Partners 1,796,919 13.55% 16.66%
MC Consulting* 351,464 2.65% 3.67%
Redfish 4 listing Srl 233,333 1.76% 1.22%
CC Holding Srl 166,666 1.26% 0.87%
ETH Scientific 2,000,000 15.08% 10.43
Free float 3,640,194 25.97% 17.71%
Total 13,457,565 100% 100%
Self-owned shares 49,758

Risk factors related to the Issuer
Detailed information about the Issuer, including its business, financial information, results, outlook and related risk factors, is contained in the 2023 annual financial report for the financial year ended December 31, 2023, published on July 8, 2024. This document, together with other regulated information and all the Issuer's press releases, is available on the Issuer's website (www.ikonisys-finance.com).




In conclusion, Ikonisys' capital increase through the offsetting of debt is a strategic move that strengthens the company's financial position and broadens its shareholder base. This operation reflects the confidence of investors in the company's future growth and the progress made in consolidating the new ALIKO Scientific group. The capital increase has a minimal impact on the shareholder's stake and the distribution of capital, with Cambria Co-Investment Fund and Cambria Equity Partners maintaining their significant positions. The company's risk factors are well-documented in its annual financial report, and investors are encouraged to review this information for a comprehensive understanding of the Issuer's business and financial situation.